DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®)
Hexaxim® (DTaP-IPV-Hep B-Hib) is a new, thiomersal-free, fully liquid, hexavalent combination pediatric vaccine containing diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, recombinant hepatitis B virus surface antigen produced in the yeast Hansenula polymorpha, and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid. It is currently registered in markets outside of the EU for primary vaccination of infants from 6 weeks of age and for booster vaccination up to 24 months of age. In randomized controlled trials, primary vaccination of infants with Hexaxim® using various immunization schedules was highly immunogenic for all vaccine component antigens regardless of the administration schedule, producing high levels of seroprotection or seroconversion for each antigen. Hexaxim® was as immunogenic as the comparator DTwP- or DTaP-based vaccines in these studies. The serological responses were generally sustained at high levels over a follow-up of ≈1 year, and booster vaccination at 15–18 months further enhanced the immune response. Hexaxim® was less reactogenic than a DTwP-based combination vaccine, and displayed a tolerability profile similar to those of the comparator DTaP-based combination vaccines. Thus, Hexaxim® provides effective seroprotection or seroconversion against six major childhood diseases simultaneously, both as primary and booster vaccination, and offers the benefits and convenience of a fully liquid, ready-to-use vaccine
- 1.World Health Organization. WHO recommendations for routine immunization - summary tables. 2012. http://www.who.int/immunization/policy/immunization_tables/en/. Accessed 27 Nov 2012.
- 3.World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385–400.Google Scholar
- 6.Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96.PubMedGoogle Scholar
- 10.European Medicines Agency. European Medicines Agency recommends suspension of Hexavac. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500017695.pdf. Accessed 27 Nov 2012.
- 11.European Medicines Agency. Scientific conclusions and grounds for the suspension of the marketing authorisation of Hexavac presented by the EMEA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/000298/WC500074684.pdf. Accessed 22 Nov 2012.
- 14.European Medicines Agency. Hexaxim: summary of opinion. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129095.pdf. Accessed 27 Nov 2012.
- 15.Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15–18 months compared to licensed vaccines in Turkish infants [abstract plus poster]. Presented at 5th Asian Congress of Pediatric Infectious Diseases, 23–26 Sep 2010, Taipei.Google Scholar
- 17.Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56.PubMedCrossRefGoogle Scholar
- 18.Lopez P, Arguedas A, Consuelo-Miranda M, et al. Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America. Presented at 15th International Congress on Infectious Diseases, 13–16 Jun 2012, Bangkok.Google Scholar
- 21.Madhi SA, Mitha I, Koen A, et al. Post-primary antibody persistence and immunogenicity/safety of an investigational DTaP-IPV-Hep B-PRP-T (Hexaxim™) booster vaccine compared to licensed vaccines in South Africa [abstract plus poster]. Presented at 7th Congress of the World Society for Pediatric Infectious Diseases, 16–19 Nov 2011, Melbourne.Google Scholar
- 22.Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24–30.PubMedCrossRefGoogle Scholar
- 23.World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405–19.Google Scholar
- 25.Santos-Lima E, B’Chir S, Lane A. Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) following primary series administration at 2, 4, 6 months of age in Latin America. Vaccine. doi:10.1016/j.vaccine.2012.11.087
- 26.UNICEF. Immunization: why are children dying? 2012. http://www.unicef.org/immunization/index_why.html. Accessed 28 Nov 2012.